SCHEMBL6506692

SCHEMBL6506692

Cc1c(NC(=O)OC(C)(C)C)ccc2nc(N[C@@H](Cc3c[nH]c4ccccc34)C(=O)O)oc(=O)c12

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTRB1 P17538 2/20 0.62
ELANE P08246 1/20 0.62
MAPT P10636 5/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
ACE P12821 2/20 0.46
CTSL P07711 2/20 0.46
TP53 P04637 1/20 0.46
CTSS P25774 1/20 0.46
CTSK P43235 1/20 0.46
PKM P14618 1/20 0.46
HPGD P15428 1/20 0.46
HTT P42858 1/20 0.46
TACR1 P25103 2/20 0.45
LMNA P02545 1/20 0.44
SSTR3 P32745 1/20 0.43
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.43
MAPK1 P28482 1/20 0.43
HSD17B10 Q99714 1/20 0.43
P4HB P07237 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8476287 0.92 CTRB1 (0.58) CTRB1ELANEMAPTSMN1; SMN2ACE
SCHEMBL8549802 0.89 MAPT (0.51) CTRB1ELANEMAPTSMN1; SMN2ACE
SCHEMBL6499875 0.88 ELANE (0.67) CTRB1ELANECTSSCTSK
SCHEMBL6496223 0.86 ELANE (0.72) CTRB1ELANEMAPTACECTSL
SCHEMBL6499394 0.82 ELANE (0.61) CTRB1ELANEMAPTSMN1; SMN2POLB
SCHEMBL6501287 0.81 ELANE (0.70) CTRB1ELANE
SCHEMBL6495590 0.81 ELANE (0.69) CTRB1ELANE
SCHEMBL6499165 0.81 ITGB2 (0.56) CTRB1ELANEMAPTSMN1; SMN2TP53
SCHEMBL6499066 0.80 ELANE (0.64) CTRB1ELANEACE
SCHEMBL6505597 0.80 ELANE (0.68) CTRB1ELANE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5985872-A THERAPEUTIC TREATMENT OF HERPES VIRAL INFECTION G.D. SEARLE & CO. (US) 1999-11-16 US claimed
US-20050032793-A1 2-amino-benzoxazinones for the treatment of viral infections G.D. SEARLE & CO. (US) 2005-02-10 US disclosed
US-6683077-B2 4H-3,1-BENZOXAZIN-4-ONE COMPOUNDS OF GIVEN FORMULA; HERPES INFECTIONS; ASSEMBLIN PROTEASE INHIBITORS G.D. SEARLE & CO. 2004-01-27 US disclosed
US-20030022895-A1 2-Amino-benzoxazinones for the treatment of viral infections G.D. SEARLE & CO. 2003-01-30 US disclosed
US-6380189-B1 FOR TREATING HERPES-RELATED DISORDERS G.D. SEARLE & CO. 2002-04-30 US disclosed
EP-0828721-B1 2-AMINO-BENZOXAZINONES FOR THE TREATMENT OF VIRAL INFECTIONS SEARLE & CO (US) 2001-11-14 EP disclosed
EP-1122245-A2 2-Amino-benzoxazinones for the treatment of viral infections G.D. Searle & Co. (US) 2001-08-08 EP disclosed
US-5985872-A THERAPEUTIC TREATMENT OF HERPES VIRAL INFECTION G.D. SEARLE & CO. (US) 1999-11-16 US disclosed
WO-1996037485-A1 2-AMINO-BENZOXAZINONES FOR THE TREATMENT OF VIRAL INFECTIONS G.D. SEARLE & CO. (US) 1996-11-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030022895-A1 2-Amino-benzoxazinones for the treatment of viral infections IFNAR1, IL4I1, HAX1 CTRB1 2628/4885ELANE 2176/4885MAPT 3904/4885
US-20050032793-A1 2-amino-benzoxazinones for the treatment of viral infections IFNAR1, IL4I1, ACE2 CTRB1 1716/4885ELANE 1199/4885MAPT 4228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.